Anti-DNA antibodies in the pathogenesis of lupus nephritis - The emerging mechanisms

被引:90
作者
Yung, Susan [1 ]
Chan, Tak Mao [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
lupus nephritis; Anti-DNA antibodies; inflammation; mesangial cells; proximal tubular epithelial cells;
D O I
10.1016/j.autrev.2007.12.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lupus nephritis is a major organ manifestation of systemic lupus erythematosu, (SLE), that could lead to acute or chronic renal failure. Active lupus is characterized serologically by high titres of anti-DNA antibodies. Compelling evidence suggests that anti-DNA antibodies, in addition to being an important diagnostic marker, are also actively involved in the pathogenesis of lupus nephritis through their ability to bind to cell surface antigens or components of the glomerular basement membrane either directly (cross-reactivity) or indirectly (via chromatin material). Accumulating data indicate that following cellular binding anti-DNA antibodies can be internalized, and the process is associated with induction of inflammatory cascades and alteration of cellular functions such as proliferation, viability, or morphological changes. Circulating anti-DNA antibodies represent a heterogeneous population. The nephritogenic property of sub-sets of anti-DNA antibodies stems in part from their ability to recognize intrinsic glomerular or tubular structures. However, recent data have shown that lupus nephritis could develop in some animal models in the absence of anti-DNA antibodies, suggesting that nephritogenicity is not an exclusive or unique property of these antibodies. This review will discuss the mechanisms through which anti-DNA antibodies mediate tissue injury and initiate inflammatory processes in the kidney. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:317 / 321
页数:5
相关论文
共 41 条
  • [1] ALARCONSEGOVIA D, 1983, CLIN EXP IMMUNOL, V52, P365
  • [2] Development of autoantibodies before the clinical onset of systemic lupus erythematosus
    Arbuckle, MR
    McClain, MT
    Rubertone, MV
    Scofield, RH
    Dennis, GJ
    James, JA
    Harley, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) : 1526 - 1533
  • [3] BERDEN JHM, 1989, NEPHROLOGIE, V10, P127
  • [4] BERNSTEIN KA, 1995, J IMMUNOL, V154, P2424
  • [5] Cameron JS, 1999, J AM SOC NEPHROL, V10, P413
  • [6] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
    Chan, TM
    Li, FK
    Tang, CSO
    Wong, RWS
    Fang, GX
    Ji, YL
    Lau, CS
    Wong, AKM
    Tong, MKL
    Chan, KW
    Lai, KN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) : 1156 - 1162
  • [7] Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
    Chan, TM
    Tse, KC
    Tang, CSO
    Mok, MY
    Li, FK
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04): : 1076 - 1084
  • [8] Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus
    Chan, TM
    Leung, JKH
    Ho, SKN
    Yung, S
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05): : 1219 - 1229
  • [9] Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus
    Christensen, SR
    Kashgarian, M
    Alexopoulou, L
    Flavell, RA
    Akira, S
    Shlomchik, MJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (02) : 321 - 331
  • [10] SLE: challenges and candidates in human disease
    Croker, JA
    Kimberly, RP
    [J]. TRENDS IN IMMUNOLOGY, 2005, 26 (11) : 580 - 586